A set of small molecules ERα biomodulators that kill therapy-resistant ERα positive breast, ovarian, and endometrial cancer cells. These small molecules have increased therapeutic potential because of an increased ability to kill therapy-resistant breast cancer cells compared to BHPI and other conventional therapies (endocrine therapies, tamoxifen and fulvestrant/ICI). The new compounds do not only inhibit proliferation of the cancer cells but actually kills them, which prevents reactivation of tumors years later.
Original languageEnglish (US)
U.S. patent number11046647
StatePublished - Jun 29 2021


Dive into the research topics of 'Activators of the unfolded protein response'. Together they form a unique fingerprint.

Cite this